Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

[1]  A. McConnachie,et al.  Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study , 2016, The Lancet.

[2]  D. Kondziolka,et al.  Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study , 2016, Stroke.

[3]  J. Aronowski,et al.  Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  A. Demchuk,et al.  Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials , 2016, The Lancet.

[5]  C. Kleinschnitz,et al.  Regulatory T Cells in Post-stroke Immune Homeostasis , 2016, Translational Stroke Research.

[6]  Reint K Jellema,et al.  Multipotent adult progenitor cells for hypoxic-ischemic injury in the preterm brain , 2015, Journal of Neuroinflammation.

[7]  Daniel-Christoph Wagner,et al.  Stem Cell–Based Tissue Replacement After Stroke: Factual Necessity or Notorious Fiction? , 2015, Stroke.

[8]  Xiaoming Hu,et al.  Functional Role of Regulatory Lymphocytes in Stroke: Facts and Controversies , 2015, Stroke.

[9]  N. Khandelwal,et al.  Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke: A Multicentric, Randomized Trial , 2014, Stroke.

[10]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[11]  L. Wechsler,et al.  A Double-Blind Placebo-Controlled Clinical Evaluation of Multistem for the Treatment of Ischemic Stroke , 2014, International journal of stroke : official journal of the International Stroke Society.

[12]  Steven C Cramer,et al.  Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials. , 2014, Stroke.

[13]  P. Wilmarth,et al.  Dissection of the Human Multipotent Adult Progenitor Cell Secretome by Proteomic Analysis , 2013, Stem cells translational medicine.

[14]  Michael D Hill,et al.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.

[15]  Max Wintermark,et al.  A trial of imaging selection and endovascular treatment for ischemic stroke. , 2013, The New England journal of medicine.

[16]  J. Grotta,et al.  Changes in Spleen Size in Patients with Acute Ischemic Stroke: A Pilot Observational Study , 2013, International journal of stroke : official journal of the International Stroke Society.

[17]  J. Grotta,et al.  Intravenous autologous bone marrow mononuclear cells for ischemic stroke , 2011, Annals of neurology.

[18]  A. Luttun,et al.  Differentiation Potential of Human Postnatal Mesenchymal Stem Cells, Mesoangioblasts, and Multipotent Adult Progenitor Cells Reflected in Their Transcriptome and Partially Influenced by the Culture Conditions , 2011, Stem cells.

[19]  Michael Chopp,et al.  Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II , 2011, Stroke.

[20]  Thorsten Dickhaus,et al.  Epigenetic quantification of tumor-infiltrating T-lymphocytes , 2011, Epigenetics.

[21]  Shinil K. Shah,et al.  Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes , 2010, Experimental Neurology.

[22]  O. Bang,et al.  A Long‐Term Follow‐Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke , 2010, Stem cells.

[23]  D. Hess,et al.  Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke , 2010 .

[24]  S. Savitz,et al.  Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. , 2009, Stem cells and development.

[25]  P. Hurn,et al.  Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression , 2009, Neuroscience.

[26]  P. Streeter,et al.  Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. , 2009, Cellular immunology.

[27]  A. Maitra,et al.  Global Characterization and Genomic Stability of Human MultiStem, A Multipotent Adult Progenitor Cell. , 2009, Journal of stem cells.

[28]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[29]  P. Hurn,et al.  Experimental Stroke Induces Massive, Rapid Activation of the Peripheral Immune System , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  C. Verfaillie,et al.  Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. , 2002, Experimental hematology.

[31]  Catherine M. Verfaillie,et al.  Pluripotency of mesenchymal stem cells derived from adult marrow , 2002, Nature.

[32]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[33]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[34]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.